HILDEN, Germany and GERMANTOWN, Maryland, June 1, 2016 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN's GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights Tumor Panel, a member of the growing family of GeneRead QIAact Panels, is the industry's first complete Sample to Insight NGS solution for both non-invasive liquid biopsies and FFPE tissue samples. The panel is now optimized for NGS analysis of blood plasma using proven automated QIAGEN sample technologies for circulating cell-free DNA (cfDNA), enabling both tumor characterization and monitoring of cancer resistance markers as a complement to initial tissue biopsies.
"The QIAact Actionable Insights Tumor Panel is now also available as a reliable solution for liquid biopsies, tracking a broad range of biomarkers to add valuable insights on the progression of cancers - and making NGS more accessible for any clinical cancer research laboratory using our GeneReader NGS System," said Kai te Kaat, Vice President of QIAGEN's Oncology Franchise. "This new application of the QIAact panel underscores QIAGEN's leadership in liquid biopsies and our commitment to deliver on the promise of NGS. The liquid biopsy workflow, which detects hundreds of critical variants in 12 clinically actionable cancer genes, is the second QIAact panel application in our expanding menu of molecular content for the GeneReader NGS System."
Click here for full press release.
John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: firstname.lastname@example.org ir.qiagen.com
SOURCE QIAGEN N.V.